Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Innate Pharma S.A. - American Depositary Shares (IPHA) 
Company Research Source: Business Wire
Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndromeIPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dose reachedMonalizumab PACIFIC-9 on track to deliver data in H2 2026Cash position of € 56.4 million1 as of September 30, 2025, anticipated cash runway until end Q3-2026Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2025.“This quarter highlights strong execution across our key programs,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and potential accelerat Show less Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IPHA alerts
Opt-in for
IPHA alerts

from News Quantified
Opt-in for
IPHA alerts

from News Quantified